<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">arthyper-924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Профилактика мозгового инсульта: возможности современной терапии</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Государственный научно-исследовательский центр профилактической медицины МЗ и СР РФ</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>28</day><month>04</month><year>2004</year></pub-date><volume>10</volume><issue>2</issue><fpage>114</fpage><lpage>117</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Марцевич С.Ю., 2004</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="ru">Марцевич С.Ю.</copyright-holder><copyright-holder xml:lang="en">Марцевич С.Ю.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/924">https://htn.almazovcentre.ru/jour/article/view/924</self-uri><abstract><p>Мозговой инсульт (МИ), по определению ВОЗ, является «клиническим синдромом с быстрым началом, который характеризуется локальным (или глобальным, как при субарахноидальном кровоизлиянии) дефицитом мозгового кровообращения, продолжается более 24 ч (или приводит к смерти в более ранний срок) и не имеет никакой другой явной причины, кроме сосудистой» [<xref ref-type="bibr" rid="cit1">1</xref>]. Существует три основных типа МИ: ишемический (частота среди лиц белой расы около 80 %), первичный интрацеребральный геморрагический (около 15 %) и субарахноидальный геморрагический (около 5 %) [<xref ref-type="bibr" rid="cit1">1</xref>].</p></abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Warlow C., Sudlow С., Dennis M. et al. Stroke. Lancet 2003; 362: 1211-24.</mixed-citation><mixed-citation xml:lang="en">Warlow C., Sudlow С., Dennis M. et al. Stroke. Lancet 2003; 362: 1211-24.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Furberg С. Natural statins and stroke risk. Circulation 1999; 99: 185-8.</mixed-citation><mixed-citation xml:lang="en">Furberg С. Natural statins and stroke risk. Circulation 1999; 99: 185-8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">D'Agostinio R.B., Wolf P.A., Belanger A.J., Kannel W.B. Stroke risk profile: adjustment for antihyperlansive medication: the Framingham Study. Stroke 1994: 25: 40-3.</mixed-citation><mixed-citation xml:lang="en">D'Agostinio R.B., Wolf P.A., Belanger A.J., Kannel W.B. Stroke risk profile: adjustment for antihyperlansive medication: the Framingham Study. Stroke 1994: 25: 40-3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G. Prevention and treatment of stroke in patients with hypertension. Clin Therapeutics 2004; 26: 631-48.</mixed-citation><mixed-citation xml:lang="en">Mancia G. Prevention and treatment of stroke in patients with hypertension. Clin Therapeutics 2004; 26: 631-48.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А., Деев А.Д., Вихирева O.В. и др. Распространенность артериальной гипертонии в России. Информироанность, леченые, контроль. Профилактика заболеваний и укрепление здоровья 2001; 2: 3-7.</mixed-citation><mixed-citation xml:lang="en">Шальнова С.А., Деев А.Д., Вихирева O.В. и др. Распространенность артериальной гипертонии в России. Информироанность, леченые, контроль. Профилактика заболеваний и укрепление здоровья 2001; 2: 3-7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chobanian A.М., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention. Detection. Evaluation, and Treatment of High Blood Pressure. JAMA 2003: 289: 2560-72.</mixed-citation><mixed-citation xml:lang="en">Chobanian A.М., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention. Detection. Evaluation, and Treatment of High Blood Pressure. JAMA 2003: 289: 2560-72.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hodge J.V., McQueen E.G., Smirk F.H. Results of hypotensive therapy in arterial hypertension based on experience with 497 patients treated and 156 controls, observed for periods of one to eight years. BMJ 1961, 1: 1-6.</mixed-citation><mixed-citation xml:lang="en">Hodge J.V., McQueen E.G., Smirk F.H. Results of hypotensive therapy in arterial hypertension based on experience with 497 patients treated and 156 controls, observed for periods of one to eight years. BMJ 1961, 1: 1-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hamilton M., Thompson E.N., Wisniewski T.K.W. The role of blood pressure control in preventing complications of hypertension. Lancet 1964: 1: 235 -8.</mixed-citation><mixed-citation xml:lang="en">Hamilton M., Thompson E.N., Wisniewski T.K.W. The role of blood pressure control in preventing complications of hypertension. Lancet 1964: 1: 235 -8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Veterans Administration Co-operative Study Croup. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967: 202: 1028-34.</mixed-citation><mixed-citation xml:lang="en">Veterans Administration Co-operative Study Croup. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967: 202: 1028-34.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990: 335: 827-38.</mixed-citation><mixed-citation xml:lang="en">Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990: 335: 827-38.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomised trial. Lancet 2004; online publication http://image.thelancet.com/extras/04art4187web.pdf.</mixed-citation><mixed-citation xml:lang="en">Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomised trial. Lancet 2004; online publication http://image.thelancet.com/extras/04art4187web.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S., Sleight P., Pogue J. et al. for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.</mixed-citation><mixed-citation xml:lang="en">Yusuf S., Sleight P., Pogue J. et al. for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Opie L., Schall R. Evidence-based evaluations of calcium channel blockers for hypertension. J Am Coll Cardiol 2002; 39: 315-22.</mixed-citation><mixed-citation xml:lang="en">Opie L., Schall R. Evidence-based evaluations of calcium channel blockers for hypertension. J Am Coll Cardiol 2002; 39: 315-22.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Staessen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002: 15: 85S-93S.</mixed-citation><mixed-citation xml:lang="en">Staessen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002: 15: 85S-93S.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Heart Protection Study Collaborative Croup. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk, individuals. A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.</mixed-citation><mixed-citation xml:lang="en">Heart Protection Study Collaborative Croup. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk, individuals. A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Di Napoli P., Taccardi A.A., Oliver M. De Caterina S. Statins and stroke: evidence for cholesterol-independent effects. Eur Haert J 2002; 23: 1908-21.</mixed-citation><mixed-citation xml:lang="en">Di Napoli P., Taccardi A.A., Oliver M. De Caterina S. Statins and stroke: evidence for cholesterol-independent effects. Eur Haert J 2002; 23: 1908-21.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sever P.S., Dahlof B., Poulter N.R. Et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastain in patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LIA): a multicentre randomised controlled trial. Lancet 2003: 361: 1149-58.</mixed-citation><mixed-citation xml:lang="en">Sever P.S., Dahlof B., Poulter N.R. Et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastain in patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LIA): a multicentre randomised controlled trial. Lancet 2003: 361: 1149-58.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
